FDA cleared edge Coapt has an FDA Class II-cleared myoelectric prosthesis control system (Complete Control), signaling a credible regulatory pathway and quicker go-to-market for related adaptive device solutions.

Growth opportunity With 11-50 employees and revenue in the 1–10 million range, Coapt appears to be a nimble, growing player open to partnerships, channel distribution, and scalable manufacturing collaborations to expand market reach.

Clinical focus A strong emphasis on research, clinical implementation, and human machine interface innovation suggests opportunities for clinical trials, training programs, and shared risk-reducing pilots with hospitals and rehab centers.

Tech stack leverage Utilizes ML-enabled control and a robust tech stack (MATLAB, AWS, LabVIEW, etc.), indicating openness to software integrations, data analytics services, cloud-based updates, and remote monitoring partnerships.

Market positioning Positioned alongside competitors like Unlimited Tomorrow, Coapt targets the medical device and prosthetics market with innovative products, offering cross-sell potential for related devices, accessories, and value-added services.